Heart Failure Clinical Trials

Find Heart Failure Clinical Trials Near You

A Phase 4, Open-label, Multi-group Study of Rezdiffra® in Combination With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and Moderate to Advanced (F2-F3) Fibrosis, Administered According to Their Approved Labeling

Status: Recruiting
Location: See all (16) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

To determine the safety of Rezdiffra (Resmetirom) when administered alongside common prescriptions for Diabetes Metellus (Farxiga/dapagliflozin \& Actos/pioglitazone)

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

‣ All Subjects:

• Willing to participate in the study and provide written informed consent.

• Meets all requirements per REZDIFFRA Prescribing Information, in the opinion of the PI.

• Male and female adults ≥18 of age at time of screening.

• Evidence of hepatic steatosis consistent with MASH demonstrated by an MRI-PDFF fat fraction \>5% obtained during second screening period.

• Evidence of moderate-to-advanced fibrosis (F2-F3) without cirrhosis.

• Stable medical conditions and background medications (non-concomitant medications as defined in this protocol) per PI judgement.

• Female subjects of reproductive potential are eligible if they have a negative serum pregnancy test (beta human chorionic gonadotropin), are not breastfeeding, and do not plan to become pregnant during the study and agree to use 1 highly effective birth control method during the study and for at least 30 days after newly introduced medication administration.

• Highly effective birth control methods include hormonal and non-hormonal intrauterine device, combination estrogen-progesterone hormonal contraception (oral, transdermal, or vaginal), tubal ligation, a vasectomized or sterile male partner, or sexual abstinence (defined as refraining from heterosexual intercourse), from Screening throughout the study, and for at least 30 days after newly introduced medication administration. Reliance on abstinence from heterosexual intercourse is acceptable only if it is the subject's habitual practice. NOTE: Female subjects who are not of child-bearing potential (ie, surgically \[bilateral oophorectomy, hysterectomy\] or naturally sterile \[\>12 consecutive months without menses\]) do not require contraception during the study.

• Must be taking a stable dose of ACTOS/pioglitazone for at least 2 months prior to Baseline. (Group A1)

• Must be taking a stable dose of FARXIGA/dapagliflozin for at least 2 months prior to Baseline. (Group A2)

⁃ Must be taking a stable dose of REZDIFFRA for at least 2 months prior to Baseline. (Groups B1 and B2)

⁃ Must not have previously taken RESMETIROM or ACTOS/pioglitazone or FARXIGA/dapagliflozin. (Group C)

⁃ For Groups A1, B1, and C1: Meets all requirements per ACTOS/pioglitazone Prescribing Information, in the opinion of the PI.

⁃ For Groups B1 and C1: (ie, naïve to ACTOS/pioglitazone): HbA1c at screening ≥7.0% and ≤10.0%.

⁃ For Groups A2, B2, and C2: Meets all requirements per FARXIGA/dapagliflozin Prescribing Information, in the opinion of the PI.

⁃ For Groups B2 and C2 (ie, naïve to FARXIGA/dapagliflozin): HbA1c at screening ≥7.0% and ≤10.0%.

Locations
United States
Arkansas
Arkansas Gastroenterology
NOT_YET_RECRUITING
North Little Rock
Arizona
Arizona Liver Health - Chandler
NOT_YET_RECRUITING
Chandler
California
Southern California Research Center
NOT_YET_RECRUITING
Coronado
Inland Empire Liver Foundation
NOT_YET_RECRUITING
Rialto
Florida
Florida Research Institute
NOT_YET_RECRUITING
Lakewood Rch
Gastro Health PLLC Galloway
RECRUITING
Miami
Med Research of Florida, LLC
NOT_YET_RECRUITING
Miami
Louisiana
Elevate Clinical Research
RECRUITING
Lake Charles
North Carolina
Centricity Research - Morehead City - Multispecialty - PPDS
NOT_YET_RECRUITING
Morehead City
Ohio
Gastro Health Research
RECRUITING
Cincinnati
Tennessee
University Diabetes and Endocrine Consultants
NOT_YET_RECRUITING
Chattanooga
Texas
Texas Clinical Research Institute
NOT_YET_RECRUITING
Arlington
South Texas Endocrinology & Metabolism Center
NOT_YET_RECRUITING
Corpus Christi
The Liver Institute at Methodist Dallas Medical Center
NOT_YET_RECRUITING
Dallas
Elevate Clinical Research - McAllen - PPDS
NOT_YET_RECRUITING
Mcallen
Diabetes and Glandular Disease Clinic, PA
NOT_YET_RECRUITING
San Antonio
Contact Information
Primary
Tom Hare
info@madrigalpharma.com
267-406-0611
Time Frame
Start Date: 2026-10-07
Estimated Completion Date: 2027-11
Participants
Target number of participants: 150
Treatments
Other: Actos (pioglitazone) [Ongoing] | Resmetirom [New]
Experienced Actos/Pioglitazone + Resmetirom Naive (A1)
Other: Farxiga (dapagliflozin) [Ongoing] | Resmetirom [New]
Experienced Farxiga/Dapagliflozin + Resmetirom Naive (A2)
Other: REZDIFFRA [Ongoing] | Actos (pioglitazone) [New]
Experienced REZDIFFRA + Actos/Pioglitazone Naive (B1)
Other: REZDIFFRA [Ongoing] | Farxiga (dapagliflozin) [New]
Experienced REZDIFFRA + Farxiga/Dapagliflozin Naive (B2)
Other: Actos (pioglitazone) [New] | Resmetirom [New]
Naive Actos/Pioglitazone + Resmetirom Naive (C2)
Other: Farxiga (dapagliflozin) [New] | Resmetirom [New]
Naïve Farxiga/dapagliflozin + Resmetirom Naïve (C2)
Sponsors
Leads: Madrigal Pharmaceuticals, Inc.

This content was sourced from clinicaltrials.gov